EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 196)
eröffnet am 29.01.04 09:28:54 von
neuester Beitrag 23.12.23 12:39:57 von
neuester Beitrag 23.12.23 12:39:57 von
Beiträge: 12.859
ID: 814.884
ID: 814.884
Aufrufe heute: 5
Gesamt: 1.588.543
Gesamt: 1.588.543
Aktive User: 0
ISIN: AU000000PVA7 · WKN: A0Q4DA
1,8250
EUR
-2,93 %
-0,0550 EUR
Letzter Kurs 03.05.18 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 3,0000 | +42,18 | |
| 0,6100 | +25,70 | |
| 2,0600 | +24,85 | |
| 9,9600 | +16,08 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1300 | -13,05 | |
| 1,1060 | -14,79 | |
| 1,2200 | -16,44 | |
| 23,700 | -19,52 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 45.105.115 von binda am 24.07.13 13:39:23Quelle:
http://www.finanznachrichten.de/nachrichten-2013-07/27494779…
http://www.finanznachrichten.de/nachrichten-2013-07/27494779…
24.07.2013 | 13:06
Business Wire · Mehr Nachrichten von Business Wire
pSivida Announces France's Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN
In France, patients will be reimbursed for 100% of the cost of ILUVIEN under Affection de Longue Duree, a program for severe chronic disease, such as diabetes
100% der Kosten werden erstattet
Business Wire · Mehr Nachrichten von Business Wire
pSivida Announces France's Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN
In France, patients will be reimbursed for 100% of the cost of ILUVIEN under Affection de Longue Duree, a program for severe chronic disease, such as diabetes
100% der Kosten werden erstattet
http://www.bizjournals.com/boston/blog/bioflash/2013/07/eye-…
...The statement from the company regarding the offering did not say what they money would go toward, but a prospectus filed with the Securities and Exchange Commission said it will be used “to fund further clinical development of our posterior uveitis product candidate (Iluvien), including expected Phase 3 clinical trials, to fund our other research and development programs, including Tethadur.”....
...The statement from the company regarding the offering did not say what they money would go toward, but a prospectus filed with the Securities and Exchange Commission said it will be used “to fund further clinical development of our posterior uveitis product candidate (Iluvien), including expected Phase 3 clinical trials, to fund our other research and development programs, including Tethadur.”....
Antwort auf Beitrag Nr.: 45.080.019 von binda am 19.07.13 16:36:36So sollte es sein. Aber die Ausis machen bei jeder Kleinigkeit ein TH
In der Zwischenzeit hat es mit Bev funktioniert und Sie begründet es wie ich bereits vermutet habe. Allerdings gilt die Ausgabe von neuen Aktien nur für Institutionelle.
Hi
The offering of $3.10 was made and has been placed with institutions.
I don’t think it’s a matter of pSivida needing money, but instead more along the lines of a good opportunity and conditions right to raise additional capital, so best to do it. As you know there is no guarantee on Iluvien approval by the FDA – and we really don’t know one way or another yet. I do know that pSivida has never counted the $25 million in its projections for their programs because it’s not a sure thing. That being said, there are a number of programs, primarily with Tethadur, that the company would like to advance, as well as the uveitis clinical trials and to do that requires capital – rather than wait to see if the $25M comes it made sense to do the raise at this point in time while a) the stock was strong and b) the biotech market is very hot here in us for raising funds. As you may know, once a window for financing shuts it can get very difficult. For example, a worse case scenario would have been not to raise any money, and then the market turns and worse yet suppose the FDA didn’t approve Iluvien – then pSivida would be in a very difficult position. This raise basically doubles their cash on hand (they said they had about $10M at the end of June and this additional $10 or so brings them pretty close to $20M in the bank). That’s very important and should the FDA approve Iluvien (again we have no way to know on this) then that’s just gravy of an additional $25M and the share price will no doubt reflect that going forward.
Hope this explains it.
And, very important – the company is making no predictions about the FDA – while they are optimistic this time, they recognize that we just won’t know until October.
Best,
Bev
In der Zwischenzeit hat es mit Bev funktioniert und Sie begründet es wie ich bereits vermutet habe. Allerdings gilt die Ausgabe von neuen Aktien nur für Institutionelle.
Hi
The offering of $3.10 was made and has been placed with institutions.
I don’t think it’s a matter of pSivida needing money, but instead more along the lines of a good opportunity and conditions right to raise additional capital, so best to do it. As you know there is no guarantee on Iluvien approval by the FDA – and we really don’t know one way or another yet. I do know that pSivida has never counted the $25 million in its projections for their programs because it’s not a sure thing. That being said, there are a number of programs, primarily with Tethadur, that the company would like to advance, as well as the uveitis clinical trials and to do that requires capital – rather than wait to see if the $25M comes it made sense to do the raise at this point in time while a) the stock was strong and b) the biotech market is very hot here in us for raising funds. As you may know, once a window for financing shuts it can get very difficult. For example, a worse case scenario would have been not to raise any money, and then the market turns and worse yet suppose the FDA didn’t approve Iluvien – then pSivida would be in a very difficult position. This raise basically doubles their cash on hand (they said they had about $10M at the end of June and this additional $10 or so brings them pretty close to $20M in the bank). That’s very important and should the FDA approve Iluvien (again we have no way to know on this) then that’s just gravy of an additional $25M and the share price will no doubt reflect that going forward.
Hope this explains it.
And, very important – the company is making no predictions about the FDA – while they are optimistic this time, they recognize that we just won’t know until October.
Best,
Bev
Zitat von wuenschmirwas: Du kannst auch in Deutschland handeln aber nur die A0Q4DQ , die Aktie A0Q4DA hat TH
Im übrigen habe ich eben versucht Bev unter bjedynak@janispr.com ein Mail zu schicken. Es konnte nicht zugestellt werden. Weiß jemand näheres?
Die A habe ich, somit schaue ich nur zu.
Ein TH wird doch zum Schutz ( Kurskapriolen) der Aktionäre eingeleitet, oder?
Trading Spotlight
Antwort auf Beitrag Nr.: 45.079.815 von binda am 19.07.13 16:09:27Du kannst auch in Deutschland handeln aber nur die A0Q4DQ , die Aktie A0Q4DA hat TH
Im übrigen habe ich eben versucht Bev unter bjedynak@janispr.com ein Mail zu schicken. Es konnte nicht zugestellt werden. Weiß jemand näheres?
Im übrigen habe ich eben versucht Bev unter bjedynak@janispr.com ein Mail zu schicken. Es konnte nicht zugestellt werden. Weiß jemand näheres?
Wir haben also Hausarrest und können lediglich aus dem Fenster zu schauen, wie die anderen draußen spielen.
Zitat von wuenschmirwas: Die Shares mit dem Endbuchstaben Q können noch gehandelt werden.
Nun fürs Geld einsammeln ist jetzt sicher der richtige Zeitpunkt. Aber warum brauchen die schon wieder Geld?
Hatte Psivida nicht erst Anfang des Jahres über einen Großinvestor (Orbis??) schon 30 Mio erhalten ?
Weiß irgend jemand schon mehr darüber.
Einzelheiten sind ja aus der Mitteilung nicht zu erfahren. Die wurden ja bis ca. 23. Juli angekündigt, wenn ich es recht verstanden habe.
Wieso werden die gehandelt und die anderen nicht?
A0Q4DQ
A0Q4DA
Wo/was ist der Unterschied?
In USA wird gehandelt und, der Kurs ist stabil
Durchsuchen
